54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (5/year:
In Part 1, the EPHL was
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
On 6ix: 6ix.com/news/protagonist-reports-final-results-rusfertide-phase-2-revive-study-showing-durable
Watch Protagonist Therapeutics' latest callProtagonist Therapeutics (NASDAQ:PTGX) Q4 2020 Earnings Call · Replay · Mar 10, 2021Read the transcript of Protagonist Therapeutics (NASDAQ:PTGX) Q4 2020 Earnings CallProtagonist Therapeutics, Inc. on 6ix
Story so far
- Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
- Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
- Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Earlier from Protagonist Therapeutics
- Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
- Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
- Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
- Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
- Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Later from Protagonist Therapeutics
- Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
- Protagonist Therapeutics Reports Granting of Inducement Awards
- Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
- Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Follow Protagonist Therapeutics into a list and get an email when it puts out news.
Follow Protagonist Therapeutics